The ACTICCA-1 trial is a randomized Phase III trial which looks to compare Gemcitabine and Cisplatin against Capecitabine alone (currently the standard treatment) for those who have had a resection for their cholangiocarcinoma or gall bladder cancer.
ACTICCA-1 is an international multi-centre trial, and is currently open and recruiting at 20+ centres across the UK. For details on these centres, including contact details, see:
https://www.ukctg.nihr.ac.uk/ and search for Study: ACTICCA-1
Lead investigator on the ACTICCA-1 trial in the UK:
Professor John Bridgewater
Medical Oncologist, University College Hospital London
UCL Cancer Institute
72 Huntley Street
London WC1E 6AA
The BILCAP Study
Following the result of the long running BILCAP study, those who have undergone a resection for their cholangiocarcinoma or gall bladder cancer, and who fit the eligibility criteria, are now offered Capecitabine chemotherapy.
For more information on the BILCAP result, please see: https://ammf.org.uk/2017/05/18/bilcap-results-show-chemo-improves-survival And:https://ammf.org.uk/2017/06/09/the-bilcap-study-results/
In this video Dr John Marshall of Georgetown University, and Professor John Primrose of the University of Southampton, discuss the practice-changing findings of the BILCAP study which investigated adjuvant capecitabine for biliary tract cancer (cholangiocarcinoma). The pan-European study that Professor Primrose refers to (6:09 into the interview) is the ACTICCA-1 trial.